

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human TFPI-2 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant mouse TFPI-2 is observed and less than 5% cross-reactivity with recombinant human TFPI-1 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TFPI-2 Asp23-Lys213 Accession # P48307
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Neutralization	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunoprecipitation	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Human Tissue Factor Pathway Inhibitor 2 (TFPI-2), also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF-1), is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains (residues 36 to 86, 96 to 149 and 158 to 208) separated with by two linker regions, and a C-terminal basic region (1-3). Expression of TFPI-2 is down-regulated in several cancers, which may contribute to tumor progression in these cancers (4). The purified recombinant human TFPI-2 ends at residue 213 and does not contain the last 22 residues (residues 214 to 235) in the C-terminal region. It inhibits the activity of recombinant human Coagulation Factor VII (R&D Systems, Catalog # 2338-SE) in the presence of recombinant human Tissue Factor (R&D Systems, Catalog # 2339-PA).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.